AstraZeneca reports positive Phase III lung cancer trial results
AstraZeneca’s DeLLphi-305 Phase III trial says a combination of Imfinzi with Amgen’s Imdelltra produced statistically significant, clinically meaningful overall survival improvement in ES-SCLC patients.